Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 27 Thoracic 12 Genitourinary 11 Gastrointestinal 11 Lymphoid 10 Other hematologic neoplasm 9 Dermatologic 6 Gynecologic 5 CNS 4 Myeloid 3 Other solid neoplasm 2 Head & Neck 2 Endocrine 2 Classical hematology 2 Sarcoma 1 Plasma cell 1 NET 1

Conditions

Recurrence 1 Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48 Everolimus 40 Magnetic Resonance Spectroscopy 21 lanreotide 17 Temozolomide 17 gallium Ga 68 dotatate 15 Octreotide 15 pembrolizumab 13 Nivolumab 13 surufatinib 12 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sunitinib 10 pasireotide 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 Lutetium-177 9 3-Iodobenzylguanidine 9 Ga(III)-DOTATOC 8 Carboplatin 8 telotristat ethyl 6 copper dotatate CU-64 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Ipilimumab 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

entinostat × NET × Clear all

NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Columbia University

Phase 2 Terminated

5 enrolled 9 charts

Recurrence, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡